FDA Approves New Drug for Rare Thyroid Cancer

by Kathy Jones on  November 30, 2012 at 2:55 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

The U.S. Food and Drug Administration (FDA) has approved a new drug called Cometriq to treat a rare form of thyroid cancer called medullary thyroid cancer that has spread to other parts of the body.
 FDA Approves New Drug for Rare Thyroid Cancer
FDA Approves New Drug for Rare Thyroid Cancer

In a released statement following the drug approval, the FDA said that 56,000 cases of thyroid cancer are diagnosed annually in the US. Among these cases, medullary cancer accounts for about 4% of the diagnosis.

Cometriq is a kinase inhibitor that can block the proteins linked to cancer cell development and growth. The FDA approval was based on the results of a clinical trial involving 330 people with medullary thyroid cancer. Patients who were administered Cometriq survived an average of 11.2 months without tumor growth, compared with an average of four months among the placebo group.

The FDA release added that the benefits and risks must be weighed before prescribing Cometriq as the drug can cause severe and fatal colon bleeding.

San Francisco-based Exelixis markets this drug.


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Iodine Deficiency Disorder Hyperthyroidism Hypothyroidism Cancer and Homeopathy Clinical Trials - Different Phases of the trial Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...